Загрузка...
A systematic assessment of chemical, genetic, and epigenetic factors influencing the activity of anticancer drug KP1019 (FFC14A)
KP1019 ([trans-RuCl(4)(1H-indazole)(2)]; FFC14A) is one of the promising ruthenium-based anticancer drugs undergoing clinical trials. Despite the pre-clinical and clinical success of KP1019, the mode of action and various factors capable of modulating its effects are largely unknown. Here, we used t...
Сохранить в:
| Опубликовано в: : | Oncotarget |
|---|---|
| Главные авторы: | , , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
Impact Journals LLC
2017
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5716741/ https://ncbi.nlm.nih.gov/pubmed/29228701 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.21416 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|